Bright start: Orthocell shines with first Remplir surgery in Hong Kong

• First surgical case using Orthocell’s flagship nerve repair product Remplir undertaken in Hong Kong
• Remplir launched at Hong Kong Orthopaedic Association 45th Annual Congress
• Hong Kong serves as strategic entry point into the Guangdong–Hong Kong–Macao Greater Bay Area

Special Report: The first surgical case using Othocell’s flagship nerve repair product has been undertaken in Hong Kong with Remplir successfully launched at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.

The achievements mark important milestones in Orthocell’s (ASX:OCC) Asia Pacific commercialisation and follows appointment of MontsMed as the company’s exclusive distributor for Remplir in Hong Kong.

In partnership with MontsMed, Orthocell officially launched Remplir at the HKOA 45th Annual Congress held over the weekend.

Orthocell said the congress provided an opportunity to introduce Remplir to key opinion leaders and specialists in orthopaedic and reconstructive surgery.

Remplir’s clinical advantages in nerve repair and the growing body of evidence supporting improved patient outcomes were highlighted at the event.

Gateway to Greater Bay growth

The first surgical case using Remplir in Hong Kong represents the start of clinical use and commercial sales in the region.

The company said with regulatory approval secured and a strong local distributor it was positioned to drive market penetration through leading hospitals and specialist surgeons.

Hong Kong serves as a strategic entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA), a region encompassing nine major cities and a population of around 100 million people.

Under Hong Kong’s Regulatory Innovation and Development of Pharmaceutical and Medical Device work plan, Hong Kong–registered medical devices such as Remplir can be imported by designated GBA healthcare institutions to meet urgent clinical needs, opening the door for broader regional uptake.

Momentum building globally

Orthocell continues to build  global commercialisation momentum since launching Remplir in Australia in 2022.

Initial surgeries using Remplir have been completed in Singapore, the US, and now Hong Kong in the past 12 months.

Sales in the Canada US$75 million nerve-repair market,  and Thailand are expected to start in the near term, supported by local distributor partnerships.

Orthocell’s Asian distributor network and regional commercial strategy will be overseen by its newly appointed commercial director Mr Hamish Thrum, who brings extensive experience across the Australian and New Zealand and APAC medical device sectors.

In the US, where Remplir is targeting a US$1.6 billion nerve repair market, in-country representatives are working with distributors to gain hospital approvals, onboard surgeons, and expand the number of active accounts.

‘Compelling opportunity for expansion’

CEO and managing director Paul Anderson said Hong Kong represented a significant opportunity for growth for Orthocell.

“Completion of our first Remplir surgical case and successful launch at the Hong Kong Orthopaedic Association Annual Congress represent important progress in our deliberate and considered approach to commercialising Remplir across Asia,” he said.

“Hong Kong’s advanced healthcare system and its role as a gateway to the Greater Bay Area present a compelling opportunity for expansion.

“We are pleased to be working with MontsMed to build awareness and drive adoption among leading surgeons.”

With more than $50 million in cash and no debt, Orthocell remains well funded to execute its growth plans and drive product adoption.

This article was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.